Lustgarten Foundation
3.
CAI CLINICAL TRIALS IN PROGRESS PASS-01 ( P ANCREATIC A DENOCARCINOMA S IGNATURE S TRATIFICATION FOR TREATMENT)
“
A united team of pioneering pancreatic cancer researchers from the United States and Canada is conducting the PASS-01 trial designed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of their tumors. In December 2020, the phase 2 trial was launched to look more closely at the two standard of care chemotherapy regimens for advanced pancreatic cancer. The goal of the PASS-01 trial is to uncover more about how the two treatments work. Precision medicine for pancreatic cancer patients includes a comprehensive evaluation of the tumor’s genomic profile. But doctors still do not know enough about the distinct types of pancreatic cancer to determine whether either treatment will help an individual patient, and if so, which treatment might work best. The study includes an in-depth analysis of each participant’s tumor
and response to therapy including generating a tumor organoid for each trial participant. An organoid is a revolutionary 3-dimensional cell culture of a patient’s specific tumor, and the scientific centerpiece of this study. Researchers will use the organoid to analyze the tumor’s biology and drug sensitivity and apply this data to determine if organoids can predict the most effective treatment for each patient. If successful, this trial can pave the way for organoids to personalize therapies for metastatic pancreatic cancer patients. The organoid work for the PASS-01 trial is being conducted at the newly opened, state-of-the-art clinical testing facility established based on the work from the dedicated Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory in New York State.
THERE IS A CRITICAL NEED TO IDENTIFY WAYS THAT MEDICINE CAN BETTER TREAT PANCREATIC CANCERS. WE BELIEVE BY IDENTIFYING AND LEARNING MORE ABOUT BIOMARKERS AND RESISTANCE PATHWAYS IN THE CANCER, WE CAN HELP MAKE THAT HAPPEN. WE CAN GIVE PATIENTS MORE HOPE THAT THEIR CANCERS CAN BE TREATED EFFECTIVELY. ” —Elizabeth Jaffee, MD, Chief Medical Advisor, Lustgarten Foundation
This trial is funded through the Gail V. Coleman and Kenneth M. Bruntel Organoids for Personalized Therapy Grant.
Powered by FlippingBook